Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients
- 99 Downloads
Both temozolomide (TMZ) and fotemustine (FTM) are considered to be active agents in recurrent glioblastoma. The objective of this study is to assess the efficacy and toxicity profile of a sequential combination of TMZ and FTM in recurrent glioblastoma after standard treatment with TMZ and radiotherapy. The rationale for evaluating this regimen was, in part, the single-agent activity of both agents against recurrent glioblastoma. Furthermore, temozolomide seems to reduce O6-alkylguanine DNA alkyltransferase (AGAT) activity in vitro, suggesting that temozolomide might enhance the antitumor activity of fotemustine by reducing AGAT activity .
Methods and statistical analysis
We planned to treat consecutive patients with recurrent glioblastoma (histologically proven at first diagnosis) after chemoradiation treatment with temozolomide and successive adjuvant temozolomide. The study was designed according to Simon minimax two-stage design (settings: P0 = 0.10, P1 = 0.25, a = 0...
KeywordsTemozolomide Glioblastoma Multiforme BCNU Carmustine Procarbazine
- 5.Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151PubMedCrossRefGoogle Scholar